Stonnington Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Stonnington Group’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$782K	Buy	13,200 +8,200	+164%	+$396K	0.2%	111
2022 Q4	$244K	Sell	5,000 -200	-4%	-$10K	0.07%	180
2022 Q3	$244K	Sell	5,200 -1,500	-22%	-$78.4K	0.07%	177
2022 Q2	$389K	Sell	6,700 -16,000	-70%	-$907K	0.1%	160
2022 Q1	$1.43M	Buy	22,700 +17,650	+350%	+$917K	0.34%	68
2021 Q4	$204K	Buy	+5,050	New	+$212K	0.04%	234
2021 Q3	–	Sell	-25,500	Closed	-$1.03M	–	296
2021 Q2	$1.03M	Buy	+25,500	New	+$943K	0.23%	112

Other funds holding ITCI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Stonnington Group's ITCI Position: Q1 2023 in Review

Stonnington Group increased its Intra-Cellular Therapies Inc. (ITCI) stake by 164% in Q1 2023, buying an estimated $396K and bringing the position to 13,200 shares worth $782K. The position accounts for 0.2% of the portfolio, ranked #111.

Stonnington Group first reported a position in ITCI in Q2 2021 and has held it in 7 quarters since. The position peaked at $1.43M in Q1 2022. 274 funds tracked by Wall St. Rank hold ITCI as of Q1 2023.

Stonnington Group held 13,200 shares of Intra-Cellular Therapies Inc. worth $782K as of Q1 2023.
Stonnington Group bought 8,200 Intra-Cellular Therapies Inc. shares in Q1 2023, an estimated $396K.
Intra-Cellular Therapies Inc. made up 0.2% of Stonnington Group's portfolio in Q1 2023, its #111 holding.
Stonnington Group first reported a position in Intra-Cellular Therapies Inc. in Q2 2021 and has held it in 7 quarters since.
Stonnington Group's Intra-Cellular Therapies Inc. position peaked at $1.43M in Q1 2022.
274 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2023.

Based on Stonnington Group's 13F filing for Q1 2023, filed 14 Apr 2023.